cilostazol has been researched along with Constriction, Pathological in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 9.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 7.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months." | 5.38 | Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 5.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear." | 5.24 | Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. ( Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K, 2017) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 3.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ." | 2.79 | Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why? ( Cho, YJ; Hong, KS; Kang, DW; Kim, BJ; Kim, JS; Koo, JS; Kwon, SU; Lee, JH; Lee, SH; Park, JM, 2014) |
| "Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival." | 2.78 | Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013) |
| "To prevent restenosis, 46 patients (60 PTCA sites) were treated with cilostazol alone (200 mg/day) (cilostazol group) and the remaining 56 (61 PTCA sites) were treated with other anti-platelet drugs and/or warfarin potassium (control group)." | 2.68 | Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. ( Hayashida, K; Higuchi, S; Kuga, T; Matsuguchi, T; Okamatsu, S; Shimokawa, H; Sobashima, A; Tsutsui, M; Yoshihara, S, 1996) |
| "Intracranial arterial stenosis (IAS) is the cause of about 10% of all ischemic strokes in the United States, but may account for about 40% of strokes in some populations." | 2.47 | Current management of symptomatic intracranial stenosis. ( Kasner, SE; Taylor, RA; Weigele, JB, 2011) |
| "Prevention of restenosis in the coronary vasculature has been demonstrated with cilostazol, trapidil, probucol, tranilast, nitric oxide donors, and clopidogrel." | 2.41 | Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature. ( Schainfeld, RM, 2002) |
| "We assessed whether cilostazol reduce restenosis after SFA stenting with self-expandable nitinol stent." | 1.38 | Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. ( Hirano, K; Iida, O; Nobuyoshi, M; Soga, Y; Suzuki, K; Yokoi, H, 2012) |
| "Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months." | 1.38 | Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012) |
| "Effects of cilostazol on preventing restenosis after PTA in these patients were investigated." | 1.35 | Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. ( Aoyama, T; Ishii, H; Kumada, Y; Maruyama, S; Matsubara, T; Matsuo, S; Murohara, T; Takahashi, H; Toriyama, T; Yamada, S; Yasuda, Y; Yuzawa, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchiyama, S | 2 |
| Toyoda, K | 2 |
| Okamura, S | 1 |
| Omae, K | 1 |
| Hoshino, H | 2 |
| Kimura, K | 2 |
| Kitagawa, K | 1 |
| Minematsu, K | 2 |
| Yamaguchi, T | 2 |
| Miura, T | 1 |
| Miyashita, Y | 2 |
| Hozawa, K | 1 |
| Doijiri, T | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Hashizume, N | 1 |
| Nakano, M | 1 |
| Ikeda, U | 1 |
| Kuwahara, K | 1 |
| Yuan, HW | 1 |
| Lin, YJ | 1 |
| Ji, RJ | 1 |
| Easton, JD | 1 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Tanaka, K | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Isobe, M | 1 |
| Ichihashi, S | 1 |
| Shibata, T | 1 |
| Fujimura, N | 1 |
| Nagatomi, S | 1 |
| Yamamoto, H | 1 |
| Kyuragi, R | 1 |
| Adachi, A | 1 |
| Iwakoshi, S | 1 |
| Bolstad, F | 1 |
| Saeki, K | 1 |
| Obayashi, K | 1 |
| Kichikawa, K | 1 |
| Iida, O | 4 |
| Yokoi, H | 3 |
| Soga, Y | 4 |
| Inoue, N | 1 |
| Suzuki, K | 3 |
| Yokoi, Y | 1 |
| Kawasaki, D | 3 |
| Zen, K | 2 |
| Urasawa, K | 1 |
| Shintani, Y | 1 |
| Miyamoto, A | 1 |
| Hirano, K | 3 |
| Tsuchiya, T | 1 |
| Shinozaki, N | 1 |
| Nakamura, M | 1 |
| Isshiki, T | 1 |
| Hamasaki, T | 1 |
| Nanto, S | 2 |
| Sobieszczyk, P | 1 |
| Eisenhauer, A | 1 |
| Kim, BJ | 1 |
| Hong, KS | 3 |
| Cho, YJ | 3 |
| Lee, JH | 3 |
| Koo, JS | 3 |
| Park, JM | 2 |
| Kang, DW | 2 |
| Kim, JS | 3 |
| Lee, SH | 2 |
| Kwon, SU | 3 |
| Takahara, M | 1 |
| Matoba, S | 1 |
| Dindyal, S | 1 |
| Sharma, P | 1 |
| Kyriakides, C | 1 |
| Taylor, RA | 1 |
| Weigele, JB | 1 |
| Kasner, SE | 1 |
| Yu, KH | 1 |
| Wong, KS | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Jeong, SW | 1 |
| Bae, HJ | 2 |
| Lee, BC | 1 |
| Han, MK | 1 |
| Rha, JH | 1 |
| Kim, HY | 1 |
| Mok, VC | 1 |
| Lee, YS | 2 |
| Kim, GM | 1 |
| Suwanwela, NC | 1 |
| Yun, SC | 1 |
| Nah, HW | 1 |
| Nobuyoshi, M | 1 |
| Yamaoka, T | 1 |
| Setacci, C | 1 |
| Castelli, P | 1 |
| Chiesa, R | 1 |
| Grego, F | 1 |
| Simoni, GA | 1 |
| Stella, A | 1 |
| Galzerano, G | 1 |
| Sirignano, P | 1 |
| De Donato, G | 1 |
| Setacci, F | 1 |
| Schainfeld, RM | 1 |
| Ishii, H | 1 |
| Kumada, Y | 1 |
| Toriyama, T | 1 |
| Aoyama, T | 1 |
| Takahashi, H | 1 |
| Yamada, S | 1 |
| Yasuda, Y | 1 |
| Yuzawa, Y | 1 |
| Maruyama, S | 1 |
| Matsuo, S | 1 |
| Matsubara, T | 1 |
| Murohara, T | 1 |
| Tsutsui, M | 1 |
| Shimokawa, H | 1 |
| Higuchi, S | 1 |
| Yoshihara, S | 1 |
| Hayashida, K | 1 |
| Sobashima, A | 1 |
| Kuga, T | 1 |
| Matsuguchi, T | 1 |
| Okamatsu, S | 1 |
| Hayashi, S | 1 |
| Morishita, R | 1 |
| Matsushita, H | 1 |
| Nakagami, H | 1 |
| Taniyama, Y | 1 |
| Nakamura, T | 1 |
| Aoki, M | 1 |
| Yamamoto, K | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039] | Phase 4 | 457 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | pariticipants (Number) |
|---|---|
| Cilostazol | 34 |
| Clopidogrel | 23 |
including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 15 |
| Clopidogrel | 10 |
"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 20 |
| Clopidogrel | 32 |
including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 11 |
| Clopidogrel | 7 |
ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 9 |
| Clopidogrel | 5 |
life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | events (Number) |
|---|---|
| Cilostazol | 2 |
| Clopidogrel | 6 |
4 reviews available for cilostazol and Constriction, Pathological
| Article | Year |
|---|---|
Management of patients after endovascular interventions for peripheral artery disease.
Topics: Aftercare; Angioplasty, Balloon; Ankle Brachial Index; Aspirin; Cilostazol; Clinical Trials as Topic | 2013 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Patholog | 2011 |
Restenosis: a challenge for vascular surgeon.
Topics: Animals; Arterial Occlusive Diseases; Cilostazol; Constriction, Pathologic; Humans; Secondary Preven | 2012 |
Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.
Topics: Animals; Blood Vessels; Brachytherapy; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Deliv | 2002 |
9 trials available for cilostazol and Constriction, Pathological
| Article | Year |
|---|---|
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Cilostazol effectiveness in reducing drug-coated stent restenosis in the superficial femoral artery: The ZERO study.
Topics: Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Peripheral Arteri | 2022 |
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; | 2019 |
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric | 2013 |
Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why?
Topics: Aged; Arteries; Atherosclerosis; Cholesterol, HDL; Cilostazol; Constriction, Pathologic; Disease Pro | 2014 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting S | 2017 |
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou | 2011 |
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Topics: Aged; Angiography; Arteries; Aspirin; Brain; Cilostazol; Constriction, Pathologic; Disease Progressi | 2005 |
Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Constriction, Pathologic; Coronary Disease; Corona | 1996 |
7 other studies available for cilostazol and Constriction, Pathological
| Article | Year |
|---|---|
Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports.
Topics: Aged; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; | 2020 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Path | 2019 |
Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Cilostazol; Constriction, | 2008 |
Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Chi-Square Distribution; Cilostazol; Constriction, Pat | 2012 |
Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Cilos | 2012 |
Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
Topics: Aged; Angioplasty, Balloon; Cilostazol; Constriction, Pathologic; Female; Humans; Kaplan-Meier Estim | 2008 |
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Aorta; Apoptosis; Arteriosclerosis; Blotting, Western; Cell | 2000 |